Review Article

From asymptomatic to critical illness: decoding various clinical stages of COVID-19

İlhami ÇELİK[1],* [ID], **Recep ÖZTÜRK**[2] [ID]

[1]Department of Infectious Diseases and Clinical Microbiology, Kayseri City Training and Research Hospital, University of Health Sciences, Kayseri, Turkey

[2]Department of Infectious Diseases and Clinical Microbiology, Medical School, İstanbul Medipol University, İstanbul, Turkey

Abstract: The clinical course of COVID-19 is variable, with clinical manifestation ranging from 81% mild course to 14% severe course along with 5% critical course in patients. The asymptomatic course is reported to potentially range between 20% and 70% (avg. 33%). A more severe course is seen in the elderly, those with various chronic diseases, and the immunosuppressed, where the case fatality rate is higher in these risk groups. The disease progresses with various symptoms, such as fever, cough, shortness of breath, malaise, myalgia, taste and smell disorders, diarrhea, sore throat, headache, and conjunctivitis. The disease begins with shortness of breath, indicative of lung damage, after an average of 7 to 10 days, and progresses in ARDS, sepsis, and septic shock. Some patients quickly enter shortness of breath, while others gradually develop shortness of breath and chest tightness and burning. The risk factors for a poor prognosis are age, comorbidities, and changes in laboratory tests. Secondary bacterial and fungal infections frequently develop with steroids and immunosuppressants, especially in the intensive care unit. Frequent complications in hospitalized patients include pneumonia (75%), ARDS (15%), acute renal failure (9%), and acute liver injury (19%). An increased incidence of heart damage is observed, including acute heart failure, arrhythmias, and myocarditis. Of the patients hospitalized due to COVID-19, 10%–25% present with prothrombotic coagulopathy, resulting in venous and arterial thromboembolic events. The most common extrapulmonary symptom is neuropsychiatric involvement, frequently accompanied by insomnia, an impediment to remembering, and an altered state of consciousness. During the course of COVID-19, patients undergo some pathological changes (severe lymphopenia, high levels of C-reactive protein, D-dimer, ferritin, etc.) depending on the condition and exposure level of the affected systems as shown by various laboratory tests. The relevant tests are the guiding elements of risk assessment, clinical monitoring, disease severity, and prognosis setting and therapy decision-making processes.

Key words: COVID-19, clinical features, risk factors, complications, laboratory tests

1. Introduction

Caused by the agent SARS-CoV-2 and affecting nearly every country globally, the COVID-19 pandemic has resulted in laboratory-verified cases nearing 200 million and over 4,000,000 deaths as of today [1].

SARS-CoV-2 is transmitted through the respiratory tract by droplets and contact surfaces contaminated by these droplets (mainly due to hands with the mouth, nose, and eyes). Additionally, it is transmitted airborne by droplet nuclei in clinical procedures (clinical sampling from the respiratory tract) conducted by healthcare providers [2-5].

Every patient may transmit the infection to 2–3 people on average. Transmission is likely in the early period (24–48 h earlier) when there are no symptoms of the disease [2-5]. Some variants developing worldwide during the disease process have increased contagiousness [6].

This paper discussed the varied clinical features and course of COVID-19, providing a further summary of the status of biochemical and hematological tests identified during the disease.

2. Clinical features

The incubation duration of COVID-19 ranges from 2 to 14 days; in many cases, clinical symptoms develop approximately 4 to 5 days after exposure (average incubation time is 4–5.1 days) [7-10]. A study revealed that the symptom onset occurred on average 4 days (3–7 days) after the first positive RT-PCR test [11].

The rate of patients with recent-onset symptoms (shown within 2.2 days) is 2.5%, and 97.5% of those infected were reported to have developed symptoms within 11.5 days [5,7-10].

Some publications support that those exposed to the disease without clinical symptoms are higher than

* Correspondence: ilhamicelik@hotmail.com

3284

expected (20%–70%), and these people are critical regarding transmission [2,5,10].

The virus starts to be contagious 24 to 48 h before the symptom onset and remains contagious for 7 to 12 (8) days in mild/moderate cases after the onset of symptoms, where it takes longer than 2 weeks in severe cases; however, positive PCR test results may continue for 6 to 8 weeks [2,5,10].

2.1. Severity of the disease and case fatality

COVID-19 is undergoing a critical or severe course ranging from asymptomatic infection to mild or severe respiratory failure; most infections are not severe [2,5,12-16].

The severity index is summarized in Table 1 [5,11,16] when the reported severity information is reviewed.

The infection is mild or asymptomatic in 80%–90% of the cases. Only 10% of cases are severe due to dyspnea, hypoxemia, and significant radiological impairment (>50%) of pulmonary parenchyma. About 5% of cases become critical illness and respiratory failure, pneumonia, shock, and multiorgan failure. The most severe cases are accompanied by death due to usual progression to ARDS and multiple organ failure. Generally, this is common in high-risk individuals, such as the elderly and those affected by multiple morbidities. Typically, the affected individuals show varying degrees of dyspnea and radiological symptoms [5,15-23]. In addition, respiratory failure was reported to have developed without a subjective sensation of dyspnea ("silent hypoxemia") [21]. In these cases, hypocapnia caused by compensatory hyperventilation is an accompanying finding [5].

The spectrum of disease severity and the case fatality rate may vary between countries and even between regions in countries. The estimated fatality rate among infected individuals is relatively low since many COVID-19 infections are asymptomatic, and milder infections are not diagnosed. Based on some analyses, lower and higher rates are also estimated to be between 0.15% and 1%, with significant heterogeneity by reporting location and risk groups [24,25]. The case fatality rate is between 5.8% in Wuhan of China and 0.7% in China [5,17]. There is a higher rate of critical and life-threatening illness among in-patients [19-21]. A study conducted in the US reported the fatality rate among hospitalized patients at 24%, with the fatality rate reported to be 60% in patients using mechanical ventilation in intensive care units [21].

In Italy, 12% of all the patients diagnosed with COVID-19 and 16% of hospitalized patients were admitted to intensive care units. The estimated case fatality rate was 7.2% in mid-March 2020 [5,26,27]. On the other hand, South Korea had an estimated mortality rate of 0.9% by mid-March. This might be correlated with different demographic features of the infection; the median age of the infected patients is 64 years in Italy, while the median age in Korea is around 40 years [2,5,15].

The variance between several studies is likely to result from distinct patient features (especially elderliness and comorbidities) and/or infection prevalence rates affected by the relative number of diagnostic tests performed on symptomatic individuals [2,17,28-34].

2.2. Risk factors for severe illness

Symptoms or more severe clinical courses are likely in healthy individuals of any age. However, they have mainly

Table 1. Severity of SARS CoV-2 infection, with typical features.

Severity	Indicators	Estimated prevalence
Asymptomatic	Absence of typical or atypical clinical manifestations; no changes in X-ray and/or CT scans	80%
Mild disease	Fever, cough, sore throat, nausea/vomiting, diarrhea, loss of taste or smell but no dyspnea; normal O2 saturation and usually no changes in X-ray and/or CT scans	
Moderate disease	Symptoms of mild disease plus evidence of lower respiratory tract infection (exam and/or imaging (presence of ground-glass opacities and lung consolidation), O_2 saturation ≥94% on room air	
Severe disease	Symptoms of moderate disease but O2 saturation <94%, PaO2/FiO2 <300 mmHg, respiratory frequency >30 breaths per minute, or chest imaging showed obvious lesion progression more than 50% within 24–48 h	15%
Critical disease	Symptoms of severe disease but intubated with respiratory failure, septic shock, and/or multiorgan dysfunction; ground-glass opacities (usually bilateral), lung consolidation, pulmonary nodules.	5%

been seen in the elderly or adults with underlying medical comorbidities (cardiovascular diseases, diabetes, chronic lung diseases, etc.) [2,35]. The risk factors for severe diseases are shown in Table 2. Comorbid diseases increase mortality. The rate of preexisting comorbidities was 2.7 in a subgroup of 355 patients deceased from COVID-19 in Italy, where only three patients had no underlying problems [27].

Deaths are increasing in older adults. The death rate in elderly patients was considerably higher [5,17,27-36]. A report from the Chinese Center for Disease Control and Prevention found that the case fatality rate was 12% and 15% in a group of people aged 70 to 79 years and people aged 80 years and over, respectively, contrary to the fatality rate of 2.3% in all cohort studies [17]. Similar findings have also been reported in Italy, where mortality rates were 12% for people aged 70–79 and 20% for people aged 80 and over [26]. Sixty-seven percent of the cases in 2449 patients diagnosed with COVID-19 in the US included the population aged ≥45, and similar to the findings in China, the elderly had the highest fatality rate, and the population aged ≥65 years constituted 45% of all the hospitalized patients, 53% of ICU patients, and 80% of deaths. There were no critical care patients or deaths among the population 19 years of age or younger [29].

The rate of severe or life-threatening infections and the need for intensive care were also determined at varying rates in different countries/regions and clinical series [2,5]. In males, a disproportionately high number of deaths have been reported from China, Italy, and the United States [5]. COVID-19 was observed to result in a disproportionately high rate of infection and death, possibly connected with the underlying inequalities in social determinants of health among the black population and Latinos in the United States of America [5].

Symptomatic infection is rare in children; cases are usually mild when they occur, whereas severe cases are reported [5].

Specific laboratory features, such as lymphopenia, elevated inflammatory markers (C-reactive protein [CRP], IL-6, ferritin, etc.), increased liver enzymes, increased lactate dehydrogenase (LDH), high D-dimer (>1 μg/mL), prolonged prothrombin time, high troponin, increased creatine phosphokinase (CPK), and kidney dysfunction, were associated with worse results [5,31-36] (Table 2).

Viral factors (high viral load, viremia) and other genetic factors are associated with the severity of the disease [5].

2.3. Asymptomatic infections
New case series show that asymptomatic infections, which were reported to be low at the initial diagnosis of the disease, are common (20%–70%) [5,6,16,32,33]. A publication evaluating 14 individual studies found that 33% of people infected with SARS-CoV-2 never developed symptoms [41].

Nearly half of the passengers with positive COVID-19 test results as scanned in the cruise ship "Diamond Princess" were asymptomatic during diagnosis; some of these passengers developed symptoms later [5,18]. Asymptomatic cases were found to be higher in especially in the younger population [42,43].

Even patients with asymptomatic infections likely have objective clinical abnormalities (low-grade fever, glass opacity in the scanner, irregular shading, etc.). In some asymptomatic cases, different clinical symptoms may subsequently appear [5,18,36,41].

2.4. Clinical symptoms
COVID-19 often begins with a fever (which develops after other complaints in some cases), followed by tiredness, dry cough, and muscular pain [5,14,29,36].

Other cohort studies of the patients with confirmed COVID-19 infection reported similar clinical symptoms [2,5,12,13,36]. Additionally, fever reported at very high rates in initial studies was reported at lower rates in subsequent series; the fever reported in some series was

Table 2. Proven or potential epidemiological risk factors for severe COVID-19* [5,21,28,37-40].

a) Age > 65
b) Cardiovascular disorder
c) Diabetes mellitus
d) Chronic obstructive pulmonary disease and other pulmonary diseases
e) Cancer (especially hematological malignancies, lung cancer, and metastatic disease)
f) Chronic kidney disease
g) Solid-organ or hematopoietic stem cell transplant
h) Obesity (BMI ≥ 30)
i) Smoking

BMI: Body mass index
* Among the associated risk factors, those identified clinically are presented in Table 4 below.

lower than 38 degrees (approximately 20% of the cases) [5,13]. Notably, fever was detected during hospitalization in the first publications, where the fever was detected at a high level (late period) (5, 10, 13). In a study conducted in New York, 31% of patients (>5000 patients) hospitalized for COVID-19 had a fever exceeding 38 degrees [19].

The most common severe manifestation of COVID-19 is pneumonia, characterized primarily by fever, cough, shortness of breath, and bilateral infiltrates on chest imaging [5,10,12-14]. In addition, other common features include upper respiratory tract symptoms, myalgia, diarrhea, and olfactory or gustatory disorders. While dyspnea that develops several days after symptom onset provides insight, no specific clinical feature reliably distinguishes COVID-19 from other viral respiratory tract infections [2,5,36].

COVID-19 may cause shortness of breath one week after symptoms appear, requiring in-patient treatment in nearly 20% of patients. These symptoms progress into pneumonia in some patients, accompanied by chest tightness, chest pain, and shortness of breath, especially in the elderly and those with chronic health conditions [5,36].

Many studies identifying clinical features of COVID-19 were conducted among the hospitalized populations. As many studies have revealed, clinical symptoms and their frequency are presented in Table 3 [2,5-12,36].

2.5. Clinical course
The symptomatic infection may vary from mild to critical during the disease. In most patients (80.9%), infections are mild (with symptoms like the flu) and may be treated at home, 13.8% are severe, leading to severe diseases, such as pneumonia and dyspnea; 4.7% are very severe, resulting in respiratory failure, septic shock, and multiple organ failure. These rates are partly variable in different patient groups [2,5,10-14,36].

The disease can progress during a week in some patients without severe initial symptoms. Some mild cases may rapidly become critical. Conditions in moderate cases may worsen more frequently; therefore, this group of patients should be monitored more carefully [5,36].

Patients usually arrive at the hospital on the 4th day from the first symptoms, while mild respiratory distress develops on the 5th day. From the onset of symptoms, hospitalization takes an average of 7 days (4.0–8.0), and respiratory distress occurs on day 8 on average (5.0–13.0), and ARDS on day 9 on average (8.0–14.0). Mechanical ventilation requires an average of about 10.5 days (7.0–14.0) [2,5,12,13,36].

The typical course of severe pathology includes overt dyspnea 6 days after the onset of flu-like symptoms, hospitalization after 8 days, and the need for tracheal intubation 10 days after hospitalization [2,5].

Table 3. Clinical symptoms identified in several studies [2,5,10-14,36].

Symptoms	Frequency (%)
Fever	43–98
Dyspnea	19–64
Cough	50–82
Fatigue	40–70
Loss of appetite	40–50
Expectoration	14–44
Runny nose	4–24
Sore throat	5–14
Taste and smell dysfunctions	24–60*
Headache	5–34
Diarrhea	2–19
Nausea-vomiting	3–16
Muscle pain	11–36

*Lower in some series (<10%)

Many of the patients have a good prognosis. The recovery period for mild infection seems to be approximately 2 weeks and 3 to 6 weeks for severe cases. The length of time between clinical onset and death ranges from 2 to 8 weeks [2,5,35].

Currently, the number of patients required to be hospitalized is unknown. Approximately 10%–20% of hospitalized patients require intensive care, whereas intubation is required for 3%–10%. The mortality rate for these patients is 2.5% [2,5,10,36].

The disease becomes more severe among the elderly and those suffering from other related conditions (heart disease, hypertension, kidney failure, diabetes, etc.). While the case fatality rate in the population aged under 50 years (with no additional conditions) is low, the risk of fatality is much higher (>10%) in the population aged over 60 years, especially among those aged 70–80 years [2,5,36].

Pediatric patients generally present with mild symptoms. The progression of the illness in pregnant women is similar to that observed in people of the same age group. There is no evidence of intrauterine transmission so far [2,5,36,44].

2.6. Severe and critical illness
While most patients with COVID-19 are asymptomatic or have mild SARS-CoV-2 infections, many patients have been admitted to the hospital and ICU. Mortality rates are high during the 2019 Coronavirus Disease (COVID-19) outbreak; the increase in the number of patients requiring an ICU has been overwhelming, jeopardizing most critical care capabilities in hospitals worldwide [45].

Severe and critical cases comprised 14% and 5% of laboratory-confirmed COVID-19 patients, respectively. Clinically, most patients infected with "Severe Acute Respiratory Syndrome Coronavirus 2" (SARS-CoV-2) exhibit no significant symptoms. However, almost 5% of the patients show a severe lung injury or even a "Multiple Organ Dysfunction Syndrome (MODS)," with mortality in intensive care units between 8% and 38%, depending on the country [46].

In a CDC report of 4226 individuals with COVID-19 in the United States between March and February 2020, the overall death rate for patients with COVID-19 was 2.3%, but that was for those requiring treatment and mechanical ventilation due to >50% hypoxemic respiratory failure [30].

Our clinical observations indicate that diabetes mellitus (primarily type 2) and underlying heart disease lead to a more severe and life-threatening progression of COVID-19, as well as morbid obesity and autoimmune diseases (Table 4).

2.6.1. Severe pneumonia

Severe pneumonia should be considered in patients with tachypnea, chest retraction, or inability to eat or drink. In 10% to 20% of severe patients, the airway injury inevitably develops into acute respiratory distress syndrome (ARDS), defined as the oxygen partial pressure (PaO_2) up to the proportion of inhaled oxygen (FiO_2) during 8–14 days of illness, the ratio of less than 300 mmHg, as well as resulting noncardiogenic pulmonary edema and mechanical ventilation. ARDS, as the leading cause of respiratory failure, is associated with high morbidity and mortality. Risk factors for developing severe to critical cases are advanced age, underlying comorbidities such as high blood pressure, diabetes, cardiovascular diseases, and cerebrovascular diseases [47].

Severe cases are confirmed if one of the following points is met: (a) shortness of breath, breathing rate ≥ 30 breaths/min; (b) pulse oxygen saturation (SpO_2) ≤ 93% of the room air at rest; (c) arterial oxygen partial pressure (PaO_2)/proportion of inhaled oxygen (FiO_2) ≤ 300 mmHg. At higher altitudes (over 1 km), the PaO_2/FiO_2 values should be adjusted based on the equation $PaO_2 / FiO_2 \times$ [atmospheric pressure (mmHg) / 760]; (d) patients with >50% lesion progression within 24 to 48 h on lung imaging [48]. The chest CT and the evolution of the CRP of a severe case of pneumonia are illustrated in Figures 1 a–1c.

The mean time from symptom onset to pneumonia development is about 5 days. In the meantime, from symptom onset to the commencement of severe hypoxemia and being hospitalized in the ICU is about 7–12 days [29].

Most patients have bilateral opacities on chest X-ray and tomography. The most common findings on tomography are ground-glass opacities and consolidation. In patients admitted to the ICU, acute respiratory distress syndrome (ARDS) with acute hypoxemic respiratory failure—sometimes with severe hypercapnia—is the most common complication (60%–70%), followed by shock (30%), myocardial dysfunction (20%–30%) and acute kidney injury (10%–30%). Elderly patients may develop hypoxemia without respiratory distress. Arrhythmia is observed in nearly half of the patients [49]. Some notable laboratory parameters for mild/moderate and severe/critical patients that were followed in our hospital are shown in Table 5.

2.7. Critical COVID-19

In critical cases, patients complained of respiratory failure (severe dyspnea, shortness of breath > 30/min, tachypnea, hypoxia), fever, reduced blood oxygen saturation of less than or equal to 93%, and pulmonary filtrates, shock, and multiorgan dysfunction, or even failure. Research has

Table 4. Risk factors for severe/critical diseases (unpublished data from Kayseri City Training and Research Hospital).

Demographics	Mild/moderate n = 39 (%)	Severe/critical n = 19 (%)	p
Age (mean ± SD, years)	46.5 ± 15	67.4 ±12	<0.01
Male sex	21 (54)	10 (53)	0.9
COVID-19 compatible chest CT signals	15 (38)	15 (79)	0.05
Chronic obstructive pulmonary disease	24 (36)	6 (32)	0.2
Hypertension	11 (28)	10 (52)	0,07
Diabetes mellitus	16 (19)	9 (50)	<0.01
Coronary artery diseases	15 (18)	5 (26)	0.4
Chronic renal failure	5 (6)	4 (21)	0.03
Body mass index	25 ±3.1	27.1±4.8	0.057

Figure 1. A sample for "severe disease" related to COVID-19. Thoracic CT imaging and CRP course of a 53-year-old male COVID-19 patient with hypertension and coronary artery disease as comorbidities. A) CT imaging at admission had a fever and CRP: 26 mg/dL, commenced dexamethasone at 2 × 8 mg/day. B) Progression of CT imaging on the 9th day of hospitalization. A single dose of 80 mg tocilizumab and dexamethasone 2 × 8mg/day for 10 days were ordered. C) CRP course of the patient.

also shown that, under severe conditions, patients show signs of impaired breathing, wet rattles, dull percussion, and a decrease in tactile tremor. Apart from respiratory problems, the disease also causes gastrointestinal issues like diarrhea. Laboratory tests of a complete blood count may show an average or reduced white blood count or a reduced lymphocyte count at the beginning of the onset of the disease. Patients also have higher levels of C-reactive protein. The chest CT series and the progression of the CRP of a critical case are illustrated in Figures 2a–2d.

Critical cases are recognized when one of the following points is met: (a) respiratory failure occurs, and mechanical ventilation is required; (b) shock occurs; (c) complicated

with other organ failures that require monitoring and treatment in the intensive care unit (ICU); individuals who have acute respiratory failure, septic shock, and/or multiple organ dysfunction. Patients with severe COVID-19 illness may become seriously ill due to the onset of "acute respiratory distress syndrome" (ARDS), which tends to occur approximately one week after symptoms appear [50].

2. 8. Acute respiratory distress syndrome (ARDS)
In patients with respiratory manifestations of SARS-CoV-2 infection, hypoxemic respiratory failure may occur. After the onset of shortness of breath, patients initially appear to have good lung compliance and poor lung elasticity, and an inadequate response to positive expiratory pressure (PEP);

Table 5. Laboratory features of the patients at admission time associated with severe/critical COVID-19 (unpublished data from the Kayseri City Hospital).

Variables (unit, normal values)	Patients		p
	Mild/moderate (n = 39)	Severe/critical (n = 19)	
White blood cell count, ×10³µL (4.5–10)	5.7 (4.8–7.3)	8.8 (6.5–10.3)	0.002
Neutrophils, x10³µL (1.8–7.5)	3.5 (2.6–5.1)	6.3 (3.9–9.1)	0.001
Lymphocytes, x10³µL (1.1–3.2)	1.6(1.3–1.9)	1.1 (0.8–1.7)	0.021
Lactate dehydrogenase, U/L (135–214)	210 (189–271.0)	325.5 (233.0–376.0)	0.004
Ferritin, µg/L (30–400)	123.0 (79.0–228.0)	473.0 (206.0–902.0)	0.001
C–Reactive Protein, mg/dL (0–5)	6.9 (1.7–30.6)	93.0 (47.0–137.0)	<0.001
D–dimer, µg/L (0–500)	390.0 (290.0–670.0)	1010.0 (685.0–580.0)	0.002

some patients may then progress to an acute respiratory distress syndrome, which is characterized by high elasticity and low compliance, as well as a high PEP response. In addition, it appears that endothelial damage is occurring, resulting in disruption of pulmonary vasoregulation and inadequate ventilation and perfusion. ICU admission and mechanical ventilation rates vary from report to report, possibly due to differences in age, admission threshold, mechanical ventilation, and the timing of the study conducted with the time of the pandemic [51].

Oxygenation disorder in adults:

· Mild ARDS: 200 mmHg <PaO_2/FiO_2a ≤ 300 mmHg (PEEP or CPAP ≥ 5 cmH2O).

· Moderate ARDS: 100 mmHg <PaO_2 / FiO_2 ≤ 200 mmHg (≥ 5 cmH2O with PEEP).

· Severe ARDS: PaO_2 / FiO_2 ≤ 100 mmHg (with PEEP ≥ 5 cmH2O) (52).

2. 9. Sepsis and septic shock

Patients with COVID-19 and sepsis are thought to be the most critical. The accompanying multiorgan dysfunction results from a deregulated host response to infection. Signs of organ dysfunction include severe dyspnea, low oxygen saturation, decreased urinary output, tachycardia, hypotension, cold extremities, skin patches, and impaired mental status. Laboratory evidence of other homeostatic disorders includes acidosis, lactate elevation, hyperbilirubinemia, thrombocytopenia, and

signs of coagulopathy. Blood pressure of patients with septic shock is continuously decreased despite the volume of resuscitation. They may also have an associated serum lactate level of> 2 mmol / L [53]. The chest CT series and the CRP progress of a MODS and ARDS are shown in Figures 3a–3d and Figures 4a–4d, respectively.

2. 10. Complications

Complications of COVID-19 included pneumonia, acute respiratory distress syndrome, heart damage, arrhythmia, septic shock, liver dysfunction, acute kidney injury (AKI), and multiple organ failure. Approximately 5% of COVID-19 patients and 20% of hospitalized patients present severe symptoms requiring critical care. The most common complications in hospitalized patients are pneumonia (75%), ARDS (15%), acute kidney injury [AKI (9%)], and acute liver injury (19%). A growing quantity of heart damage has been found, including increased troponin levels, acute heart failure, arrhythmias, and myocarditis. Of hospitalized COVID-19 patients, 10%–25% develop prothrombotic coagulopathy, which results in venous and arterial thromboembolic events. Neurological manifestations include altered consciousness and stroke [48]. A variety of disease-related complications and their physio-pathological mechanisms were summarized in Table 6. The thoracic CT series and CRP progression of a case complicated by pneumothorax and invasive pulmonary aspergillosis are shown in Figures 5a–5e.

Figure 2. A sample for critical disease associated with COVID-19. Thoracic CT imaging and CRP course for 51-year-old women COVID19 patient with previously undiagnosed type II diabetes mellitus. A) Thoracic computed tomography at admission. B) Thoracic CT imaging on day eight. C) Thoracic CT imaging on the 37th day. D) Patient's CRP course. Low-dose tocilizumab (100 mg, 100 mg, every other day at first CRP peak, and 80 mg, and 80 mg one dose at second CRP peak, every other day) four times (a total of 360 mg) and 250 mg three times for 3 consecutive days methylprednisolone and 40 mg/day for 20 days had been administered.

2. 11. Viral and bacterial coinfection and secondary infection in patients with COVID-19

According to current estimates, there is generally a low rate of new, real viral coinfections at the beginning of COVID-19. Reports of high coinfection rates are expected to be tempered by the limitations of current diagnostic methods. Nevertheless, more data collection is warranted, and more information about COVID-19 coinfections will provide better guidance for effective antimicrobial treatment, whether SARS-CoV-2 coinfections or genuine coinfections [55].

In a multicenter study by Russell et al. [56], 1107 patients/48,902 patients (2.26%) were identified as having COVID-19-related infections (positive blood, sputum, or deep breathing cultures). For microbiologically confirmed COVID-19-associated infections where sampling time was known, 762 (70.6%) of the 1080 infections were secondary and occurred more than 2 days after hospitalization.

Most culture-positive respiratory samples represented secondary infections (919 [4.9%] of 1082 sputum and deep respiratory cultures). In lower respiratory tract coinfections (within 2 days of admission), *Staphylococcus aureus* (17.8%), *Haemophilus influenzae* (12.7%), and *Pseudomonas aeruginosa* (9.3%) were most frequently identified in sputum. *Streptococcus pneumoniae* was infrequently cultured (4·2%). *Staphylococcus aureus* was the predominant organism (31.1%). *S. aureus* was the common cause of secondary lower respiratory tract

Figure 3. A sample for sepsis/septic shock and MODS associated with COVID-19. A 54-year-old male with type 2 diabetes complained of shortness of breath (SaO2: 77) and weakness and was monitored in the ICU. A) Chest CT at the time of admission (CT) showed a typical ground glass image that corresponded to a COVID-19 peripheral weighted bilateral multifocal patchy. B) Chest CT on day nine at hospitalization. C) Chest CT on day 23 and out of the hospital with an oxygen condenser. D) CRP course of the patient.

infections (sputum: 12.6%; deep respiratory: 10.5%), but most organisms were gram-negative, including *Escherichia coli* (14.5%), *Pseudomonas aeruginosa* (12.5%), *Klebsiella pneumoniae* (11.8%), *Klebsiella aerogenes* (6.2%), and *Citrobacter koseri* (4.0%) [57].

## 2. 12. Extrapulmonary involvement of COVID-19

2. 12. 1. Neurologic involvement

In patients with severe or critical comorbidities, neurological complications occur frequently. Central and peripheral nervous systems (CNS and PNS) may be affected during COVID-19. CNS symptoms include headache, and decreased reactivity are initial indicators of potential neurological impairment; anosmia, hyposmia, hypogeum,

and dysgeusia are also common early symptoms of coronavirus disease. Headache is a commonly occurring symptom. The most severe neurological manifestation, sensory impairment (agitation, delirium, and coma), is caused by hypoxia and metabolic abnormalities [58].

Cerebrovascular disease, particularly large-vessel ischemic strokes, and less frequently cerebral venous thrombosis, intracerebral hemorrhage, and subarachnoid hemorrhage, usually occur as part of a thrombotic state induced by viral attachment ACE2 receptors in the endothelium. In addition, acute hemorrhagic necrotizing encephalopathy is associated with cytokine storms [59].

Additionally, individual cases of convulsions, encephalopathy, meningitis, encephalitis, and myelitis

Figure 4. The same patient (a 54-year-old male) was hospitalized again after a 12-day discharge with severe signs of ARD. A) On the day of admission, he vented mechanically. B) 3rd day of re-admission, and C) 6th day of re-admission, D) The patient's CRP course lost 43rd day because of septic shock and multiple organ failure.

have been reported. However, in the case of COVID-19, neurological diseases affecting PNS and muscles are less common. They include Guillain–Barré syndrome, Miller Fisher syndrome, cranial polyneuritis, and rare cases of viral myopathy accompanied by rhabdomyolysis [60].

2. 12. 2. Psychiatric involvement

There has been an increase in anxiety, mood, sleep, substance use, and posttraumatic stress disorders after epidemics. In addition, anxiety related to illness, social and economic issues, and quarantine may cause more stress and depressive symptoms in individuals during the pandemics. In particular, people who contract the disease, those at heightened risk for it (including the elderly, people with compromised immune function, and

those living or receiving care in congregate settings), and people with preexisting medical, psychiatric, or substance use problems are at increased risk for adverse psychosocial outcomes [61].

2. 12. 3. Cutaneous involvement

In an international study, the most common dermatological morphologies were found in 171 laboratory-confirmed cases of COVID-19, including morbilliform (22%), perniform (18%), urticaria (16%), macular erythema (13%), vesicular (11%), papulosquamous (9.9%), and retiform purpura (6.4%) [62].

2. 12. 4. Cardiac involvement

Coupled with the high inflammatory load associated with cytokine release, COVID-19 can trigger vascular

Table 6. Complications of severe COVID-19 infection [54].

Complication	Inflammatory response	Structural abnormalities	Clinical outcome
Abnormal coagulation and thrombosis	Lymphopenia Thrombocytopenia IL-6, CRP D-dimer	Venous thrombosis Intravascular coagulopathy, Myocardial injury Cerebral infarction	Deep vein thrombosis DIC Myocardial infarction Stroke
Acute cardiovascular syndrome (ACovSC)	Troponin ⁻ST or ST Arrhythmias	Wall motion abnormalities, De novo systolic dysfunction Myocarditis or myocardiopathy	Heart failure Pericardial effusion Acute coronary artery disease.
Acute respiratory distress syndrome (ARDS)	Alveolar damage Influx of inflammatory cells Protein exudation	Pulmonary edema Pneumonia, Pleural effusion Secondary bacterial infection	Acute dyspnea Severe hypoxia Respiratory failure
Cytokine storm syndrome (CSS)	Macrophage activation Cytokine release Thrombin ⁻Anticoagulants	Activation of coagulation pathways Widespread microthrombi, Vascular permeability	DIC Shock Multiorgan failure

inflammation, acute myocardial injury, myocarditis, arrhythmias, venous thromboembolism, metabolic syndrome, and Kawasaki disease. The most frequently reported cardiovascular complications of COVID-19 include acute myocardial injury, myocarditis, myocardial infarction, heart failure, cardiomyopathy, arrhythmias, and venous thromboembolic events [63].

A case series evaluated cardiovascular events included 84 patients from Morocco; 50 had a pulmonary embolism (59.52%); three of them were massive. Twelve patients had a myocardial infarction (14.28%), ten had pericarditis (11.9%), and three developed myocarditis (3.57%). In addition, six patients had ischemia (7.14%), including two patients with Leriche syndrome (in one case associated with segmental pulmonary embolism), three patients with lower limb ischemia, and only 1 case of upper limb ischemia. There were also 2 cases of ischemic stroke (2.38%) and 1 case of congestive heart failure (1.19%) [64].

2. 12. 5. Renal involvement
A recently published study assessed over 1000 cases of COVID-19 in China and found that the prevalence of acute kidney injury (ARI) in these patients was 1.6% (2). Another study conducted at a university hospital in Wuhan City in China evaluated 701 COVID-19 patients and found that the overall prevalence of ARI caused by COVID-19 was 3.2% (3). Another interesting neurological conclusion was that 43.9% of patients had proteinuria when admitted, and 26.7% had hematuria. Rhabdomyolysis is commonly observed in COVID-19. It can lead to high levels of serum phosphokinase creatinine (more than five times the upper bound of the ordinary) and could be another critical factor in ARI development [65].

2. 12. 6. Endocrine involvement
To date, evidence indicates that COVID-19 can induce a functional pituitary gland by direct and indirect effects on the hypothalamus-pituitary axis, resulting in an inappropriate response to adrenal stress. Furthermore, there are several reports of potential immune damage to the thyroid gland leading to subacute thyroiditis. COVID-19 has been implicated in high blood glucose in known diabetics and the discovery of insulin resistance in previously undiagnosed people. It has also been shown that COVID-19 triggers type 1 diabetes associated with ketosis. The presence of the virus in semen currently has no apparent clinical significance [66].

**2. 12. 7. Gastrointestinal features**
The prevalence of gastrointestinal symptoms at the time of diagnosis differs from study to study, ranging from 2% to 57%. For example, in a metaanalysis of 35 studies in China, mainly conducted in the first phase of the epidemic, the clinical characteristics of 6686 COVID-19 patients were analyzed, finding a combined prevalence of gastrointestinal symptoms by 15%. In addition, transient elevations in serum aminotransferases and altered markers of liver function and bilirubin have been observed in up to 58% of patients with severe COVID-19. However, the underlying mechanisms and possible complications are still poorly understood [67].

2.12.8. Ocular involvement
In studies that reported details of observed eye symptoms, the most common eye symptoms were dry eye or foreign body sensation (16%), redness (13.3%), tearing (12.8%), itching (12.6%), eye pain (9.6%), and discharge (8.8%) [68].

3. Laboratory tests
During the course of COVID-19, patients have various pathological changes as indicated by laboratory tests. The publications on these changes in laboratory tests increased over time, and the results of different studies were initially assessed and analyzed [2,5,34-36].

Figure 5. A 73-year-old male patient was admitted to our hospital for a critical illness related to COVID-19. A) The chest computed tomography results were compatible with CORADS-5. B) Pneumothorax (red line) and invasive fungal infection are seen as a mass with a peripheral halo (orange line) of ground-glass opacification on day 20th of hospitalization in the ICU. C) Reversed halo sign (RHS) in the left upper lobe (green line) with adjacent ground-glass opacities at the 43rd day of hospitalization in ICU. D & E) Patient's CRP course. *Aspergillus niger* was recovered from bronchoalveolar lavage fluid sample, and galactomannan in bronchoalveolar lavage fluid antigen test was reported as "positive: 7.19" (0.16–0.2 index).

The disorders diagnosed upon hematological, immunological, and biochemical tests are usually diagnosed in hospitalized patients. The summary information on the tests used in this context is given in Table 7.

Laboratory tests guide severity and risk assessment, clinical monitoring, and therapy decision-making processes [34,35].

As laboratory findings in hospitalized patients, some values (CRP, sedimentation rate, LDH, ferritin, etc.) increase at varying levels along with low lymphocyte count and high liver enzymes [2,5,36].

The most common laboratory findings in COVID-19 patients are elevated CRP levels, decreased albumin levels, increased ESR, lymphopenia, eosinopenia, increased IL-6, and increased LDH.

Table 7. Common laboratory findings among hospitalized patients with COVID-19* [2,5,34-36].

Tests	Changes and interpretations
Hematological parameters (including hemostasis and coagulation)	
Complete blood count (hemogram)	Hemoglobin (usually normal, may be decreased in severe cases) Leukocyte (normal, decreased, increased (in ICU cases)) Lymphopenia (in most cases), <800 µL in severe cases Eosinopenia (in most cases) Thrombocyte (normal, increased, slightly lower in severe cases; thrombocytopenia is linked to the disease severity and the mortality risk.
CD4 and CD8	Decreased (in most cases)
PT and aPTT	Normal, slightly prolonged (in severe cases, especially in ICU cases); identification of coagulopathy
Fibrinogen	Decreased; identification of continued coagulopathy
D-dimer	Increased (in severe cases; in nonsurvivors); >1000 ng/mL: in severe cases; identification of continued consumption and thrombotic coagulopathy
Inflammatory Markers	
CRP	Increased (Higher in severe cases); > 10 × the upper limit of normal (N: <8 mg/L)
Erythrocyte sedimentation rate	Normal, increased
Ferritin	Increased (in severe cases); >500 µg/L (N: 10/30–200/300 µg/L)
Procalcitonin	Normal, Increased (In severe cases, secondary to bacterial pneumonia in ICU patients)
Il-6	Increased (according to severity: >critical>severe>mild; cytokine storm)
Biochemistry tests	
Glucose	Increased (in severe cases); a marker of metabolic balance
BUN and creatinine	Increased (in severe cases); a marker of renal damage and failure
Electrolytes	Hyponatremia, hypokalemia (hyperkalemia in some patients), Hypocalcemia; a marker of metabolic balance
Albumin	Decreased (in severe cases; a marker of liver failure; associated with increased mortality)
ALT and AST	Increased (especially in ICU cases; usually as a result of cytokine storm or drug-induced liver injury)
Total Bilirubin	Increased (in severe cases and/or prolonged cases of hospitalization); as a result of liver injury
Lactate dehydrogenase	Increased (in severe cases, in ICU cases, in ARDS cases); >245 U /L in severe cases (N: 110–210 u/L); a marker of lung injury and tissue damage
Creatine phosphokinase	Increased in severe cases; > 2 × the upper limit of normal (N: 40–150 U/L)
Troponin T/I	Increased (in severe cases), > 2 x the upper limit of normal (N: 0–9/14 ng/L)
B-type natriuretic peptide (BNP/NT-proBNP):	Increased (in severe/critical cases)

*Of these general laboratory features, the ones identified by us clinically are discussed in relevant sections above.

As revealed by several studies, the most common laboratory abnormalities reported at admission among hospitalized pneumonia patients include leukopenia (9%–34%) or leukocytosis (24%–30%), lymphopenia (63%–83%), thrombocytopenia (34%), and elevated aminotransferase (37%) and lactate dehydrogenase [2,5,10,12-14,34-36].

Increased inflammation indices, including nonincreased procalcitonin and increased CRP levels, are associated with clinical severity. At admission, many patients with pneumonia have normal serum procalcitonin levels; however, this level could likely be higher in patients who need care in ICUs [5,9,29-31]. High CRP levels were found in hypoxemic COVID patients, and a further correlation was observed between CRP and

mortality risk [2,5,34-36]. Troponin appears to be a strong prognostic marker of mortality. Additionally, D-dimer and ferritin levels were notably higher in hospitalized patients in general. If necessary, patients with increased CRP, lymphopenia and increased LDH should be followed closely and transferred to ICUs. Various laboratory features, including high D-dimer levels and more severe lymphopenia, were associated with critical disease and mortality [2,5,14,34-3].

In conclusion, COVID-19 is a novel viral disease with the potential to affect almost every system and a rich clinical spectrum, which results in varied complications and is particularly severe and fatal in the elderly or those with comorbidities, leading to pathological changes in various laboratory tests.

References

1. Ladhani SN. Crossing the Rubicon: A fine line between waiting and vaccinating adolescents against COVID-19. Journal of Infection. 2021;83(3):294-297. doi: 10.1016/j.jinf.2021.07.015

2. Jin Y, Yang H, Ji W, Wu W, Chen S et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020; 12 (4): E372. doi: 10.3390/v12040372

3. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R et al. COVID-19 diagnosis and management: a comprehensive review. Journal of Internal Medicine 2020; 288 (2): 192-20610.1111/joim.13091. doi: 10.1111/joim.13091

4. Wong SCY, Kwong RT, Wu TC, Chan JWM, Chu MY et al. Risk of nosocomial transmission of coronavirus disease 2019: an experience in a general ward setting in Hong Kong. Journal of Hospital Infection 2020; 105 (2): 119-127. doi: 10.1016/j.jhin.2020.03.036

5. McIntosh K. COVID-19: Clinical features. In: UpToDate. Hirsch MS, Bloom A (editors), UpToDate, Waltham, MA, USA, 2021.

6. Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021, Eurosurveillance 2021; 26 (24): 2100509. doi: 10.2807/1560-7917. ES.2021.26.24.2100509

7. Chan JF, Yuan S, Kok KH, To KK, Chu H et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395 (10223): 514-23. doi: 10.1016/S0140-6736(20)30154-9

8. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Annals of Internal Medicine 2020; 172 (9): 577-582. doi: 10.7326/M20-0504

9. Li Q, Guan X, Wu P, Wang X, Zhou L et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. The New England Journal of Medicine 2020; 382 (13): 1199-1207. doi: 10.1056/NEJMoa2001316

10. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ et al. Clinical Characteristics of Coronavirus Disease 2019 in China. The New England Journal of Medicine 2020; 382 (18): 1708-1720. doi: 10.1056/NEJMoa2002032

11. Sakurai A, Sasaki T, Kato S, Hayashi M, Tsuzuki SI et al. Natural History of Asymptomatic SARS-CoV-2 Infection The New England Journal of Medicine 2020; 383 (9): 885-886. doi: 10.1056/NEJMc2013020

12. Wang D, Hu B, Hu C, Zhu F, Liu X et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA: The Journal of the American Medical Association 2020; 323 (11): 1061-1069. doi: 10.1001/jama.2020.1585

13. Huang C, Wang Y, Li X, Ren L, Zhao J et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5

14. Chen N, Zhou M, Dong X, Qu J, Gong F et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395 (10223): 507-513. doi: 10.1016/S0140-6736(20)30211-7

15. He F, Deng Y, Li W. Coronavirus disease 2019 (COVID-19): What we know? Journal of Medical Virology 2020; 92 (7): 719-725. doi: 10.1002/jmv.25766

16. Baj J, Karakuła-Juchnowicz H, Teresiński G, Buszewicz G, Ciesielka M et al. COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge, Journal of Clinical Medicine 2020; 9(6): 1753. doi: 10.3390/jcm9061753

17. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA: The Journal of the American Medical Association 2020; 323: 1239–42. doi: 10.1001/jama.2020.2648

18. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eurosurveillance 2020; 25(10): 2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180

19. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA: The Journal of the American Medical Association 2020; 23 (20): 2052-2059. doi: 10.1001/jama.2020.6775

20. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020; 395 (10239): 1763-1770. doi: 10.1016/S0140-6736(20)31189-2

21. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L et al. Factors Associated With Hospital Admission and Critical Illness Among 5279 People With Coronavirus Disease 2019 in New York City: Prospective Cohort Study. the British Medical Journal 2020; 369: m1966. doi: 10.1136/bmj.m1966

22. Liu K, Chen Y, Lin R, Han K. Clinical feature of COVID-19 in elderly patients: a comparison with young and middle-aged patients. Journal of Infection 2020; 80(6): e14-e18.doi: 10.1016/j.jinf.2020.03.005

23. Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clinical Medicine Journal 2020; 20 (2): 124-127. doi: 10.7861/clinmed.2019-coron

24. Ioannidis JPA. Reconciling estimates of global spread and infection fatality rates of COVID-19: An overview of systematic evaluations. European Journal of Clinical Investigation 2021; 51 (5): e13554. doi: 10.1111/eci.13554

25. Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates. International Journal of Infectious Diseases 2020; 101: 138-148. doi: 10.1016/j.ijid.2020.09.1464

26. Grasselli G, Pesenti A, Cecconi M. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response. JAMA: The Journal of the American Medical Association 2020; 323 (16): 1545-1546. doi: 10.1001/jama.2020.4031

27. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA: The Journal of the American Medical Association 2020; 323 (18): 1775-1776 doi: 10.1001/jama.2020.4683

28. Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. European Journal of Epidemiology 2020; 35 (12): 1123-1128. doi: 10.1007/s10654-020-00698-1

29. Yang X, Yu Y, Xu J, Shu H, Xia J et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. the Lancet Respiratory Medicine 2020; 8 (5): 475-481. doi: 10.1016/S2213-2600(20)30079-5

30. CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. Morbidity and Mortality Weekly Report (MMWR) 2020; 69 (12): 343-346. doi: 10.15585/mmwr.mm6912e2

31. McMichael TM, Currie DW, Clark S, Pogosjans S, Kay M et al. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington. The New England Journal of Medicine 2020; 382 (21): 2005-2011. doi: 10.1056/NEJMoa2005412

32. Zhou F, Yu T, Du R, Fan G, Liu Y et al. Clinical course and risk factors for mortality of adult in-patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054-1062. doi: 10.1016/S0140-6736(20)30566-3

33. Wu C, Chen X, Cai Y, Xia J, Zhou X et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA International Medicine 2020; 13: e200994. doi: 10.1001/jamainternmed.2020.0994

34. Henry BM, De Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical Chemistry and Laboratory Medicine 2020; 58 (7): 1021-1028. doi: 10.1515/cclm-2020-0369

35. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clinical Chemistry and Laboratory Medicine 2020; 58 (7). doi: 10.1515/cclm-2020-0198

36. Öztürk R, Taşova Y, Ayaz A. COVID-19: pathogenesis, genetic polymorphism, clinical features and laboratory findings. *Turkish Journal of Medical Sciences 2020 21; 50(SI-1): 638-657. doi: 10.3906/sag-2005-287*

37. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C et al. Factors associated with COVID-19-related death using Open SAFELY. Nature 2020; 584 (7821): 430-436. doi: 10.1038/s41586-020-2521-4

38. Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. PLoS Medicine 2020; 17(9): e1003321. doi: 10.1371/journal.pmed.1003321

39. Lowe KE, Zein J, Hatipoglu U, Attaway A. Association of Smoking and Cumulative Pack-Year Exposure With COVID-19 Outcomes in the Cleveland Clinic COVID-19 Registry. JAMA International Medicine 2021; 181 (5): 709-711. doi: 10.1001/jamainternmed.2020.8360

40. Tartof SY, Qian L, Hong V, Wei R, Nadjafi RF et al. Obesity and Mortality Among Patients Diagnosed With COVID-19: Results from an Integrated Health Care Organization. Annals of Internal Medicine 2020; 173 (10): 773-781. doi: 10.7326/M20-3742

41. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A Systematic Review. Annals of Internal Medicine 2021; 174 (5): 655-662. doi: 10.7326/M20-6976

42. Baggett TP, Keyes H, Sporn N, Gaeta JM. Prevalence of SARS-CoV-2 Infection in Residents of a Large Homeless Shelter in Boston. JAMA: The Journal of the American Medical Association 2020; 323 (21): 2191-2192. doi: 10.1001/jama.2020.6887

43. Kasper MR, Geibe JR, Sears CL, Riegodedios AJ, Luse T et al. An Outbreak of Covid-19 on an Aircraft Carrier. The New England Journal of Medicine 2020; 383 (25): 2417-2426. doi: 10.1056/NEJMoa2019375

44. Crossette-Thambiah C, Nicolson P, Rajakaruna I, Langridge A, Sayar Z et al. The clinical course of COVID-19 in pregnant *versus* non-pregnant women requiring hospitalization: results from the multicentre UK CA-COVID-19 study. British Journal of Haematology 2021; 16. doi: 10.1111/bjh.17579

45. Van de Veerdonk FL, Netea MG. Blocking IL-1 to prevent respiratory failure in COVID-19. Critical Care 2020; 24 (1): 445. doi: 10.1186/s13054-020-03166-0

46. Beltrán-García J, Osca-Verdegal R, Pallardó FV, Ferreres J, Rodríguez M et al. Sepsis and Coronavirus Disease 2019: Common Features and Anti-Inflammatory Therapeutic Approaches. Critical Care Medicine 2020; 48 (12): 1841-1844 doi:10.1097/CCM.0000000000004625

47. Zhou M, Zhang, X, Qu, J. Coronavirus disease 2019 (COVID-19): a clinical update. Frontiers of Medicine 2020; 14 (2): 126-135. doi: 10.1007/s11684-020-0767-8

48. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020. Morbidity and Mortality Weekly Report (MMWR). 2020; 69:343-346

49. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA: The Journal of the American Medical Association 2020; 323 (16): 1612–1614. doi: 10.1001/jama.2020.4326

50. Chen X, Peng F, Zhou X, Zhu J, Chen X et al. Predicting severe or critical symptoms in hospitalized patients with COVID-19 from Yichang, China. Aging 2021; 13 (2): 1608-1619. doi:10.18632/aging.202261

51. Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. JAMA: The Journal of the American Medical Association 2020; 323 (22): 2329–2330. doi:10.1001/jama.2020.6825

52. Clinical management of COVID-19 patients: living guidance, January 25, 2021, https://app.magicapp.org/#/guideline/j1WBYn, Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020. Morbidity and Mortality Weekly Report (MMWR) 2020; 69:343-346

53. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli RD. Features, Evaluation, and Treatment Coronavirus (COVID-19) Treasure Island, FL: StatPearls Publishing; [Mar;2020]. 2020. PMID: **32150360**

54. Nikhra V. Identifying patterns in COVID-19: Morbidity, recovery, and the aftermath. International Journal of Clinical Virology 2020; 4: 056-064. doi: 10.29328/journal.ijcv.1001016

55. Cimolai N. The Complexity of Co-Infections in the Era of COVID-19. SN Comprehensive Clinical Medicine 2021; 1-13. https://doi.org/10.1007/s42399-021-00913-4

56. Russell CD, Fairfield CJ, Drake TM, Turtle L, Seaton RA et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalized with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe 2021; 2(8): e354-e365. doi: 10.1016/S2666-5247(21)00090-2

57. Langford BJ, So M, Raybardhan S, Leung V, Westwood D et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clinical Microbiology and Infection 2020; 26 (12): 1622-1629. https://doi.org/10.1016/j.cmi.2020.07.016

58. Mao L, Jin H, Wang M, Hu Y, Chen S et al. Neurologic Manifestations of Hospitalized Patients Coronavirus Disease 2019 in Wuhan, China. JAMA Neurology. 2020; 77 (6): 683-690. doi:10.1001/jamaneurol.2020.1127

59. Di Carlo DT, Montemurro N, Petrella G, Siciliano G, Ceravolo R et al. Exploring the clinical association between neurological symptoms and COVID-19 pandemic outbreak: a systematic review of current literature. Journal of Neurology 2021; 268: 1561–1569. https://doi.org/10.1007/s00415-020-09978-y

60. Acar T, Demirel EA, Afsar N, Akcalı A, Demiret GA et al. The COVID-19 from Neurological Overview. Turkish Journal of Neurology 2020; 26 (2): 58-108 doi: 10.4274/tnd.2020.73669

61. Torales J, O'Higgins M, Castaldelli-Maia JM, Ventriglio A. The outbreak of COVID-19 coronavirus and its impact on global mental health. International Journal of Social Psychiatry 2020; 66 (4): 317-320. doi: 10.1177/0020764020915212

62. Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C et al. The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries. Journal of the American Academy of Dermatology 2020; 83 (4): 1118-1129. doi: 10.1016/j.jaad.2020.06.1016

63. Chilazi, M, Duffy, E.Y, Thakkar A, Michos ED COVID and Cardiovascular Disease: What We Know in 2021. Current Atherosclerosis Reports 2021; 23: 37. https://doi.org/10.1007/s11883-021-00935-2

64. El Rhalete A, Rhazi I, Bensaid A, Zaid I, Bkiyer H et al. Cardiovascular injuries during COVID-19 infection: A PROCESS-compliant case series from Eastern Morocco. Annals of Medicine and Surgery 2021; 65: 102309. doi: 10.1016/j.amsu.2021.102309

65. Migliaccio MG, Di Mauro M, Ricciolino R, Spiniello G, Carfora V et al. Renal Involvement in COVID-19: A Review of the Literature. Infection and Drug Resistance 2021; 14: 895-903. doi: https://doi.org/10.2147/IDR.S288869

66. Garg MK, Gopalakrishnan M, Yadav P, Misra S. Endocrine Involvement in COVID-19: Mechanisms, Clinical Features, and Implications for Care. Indian Journal of Endocrinology Metabolism 2020; 24 (5): 381-386. doi: 10.4103/ijem.IJEM_440_20

67. Vespa E, Pugliese N, Colapietro F, Aghemo A. Stay (GI) Healthy: COVID-19 and Gastrointestinal Manifestations. Techniques and Innovations in Gastrointestinal Endoscopy 2021; 179-189. https://doi.org/10.1016/j.tige.2021.01.006

68. Nasiri N, Sharifi H, Bazrafshan A, Noori A, Karamouzian M et al. Ocular Manifestations of COVID-19: A Systematic Review and Meta-analysis. Journal of Ophthalmic and Vision Research 2021; 16 (1): 103-112. doi: 10.18502/jovr. v16i1.8256